17 Jul 05
Euroscicon, a new meetings organisation company in London has plugged the gap in scientific education, with a novel approach to scientific meetings. Meetings include hot areas of research such as stem cells, microarrays, live cell imaging and proteomics both mirror current scientific emphasis and set the tone for future advances.
Dr Shara Cohen
15 Jul 05
Pfizer has announced that it is to discontinue the development of its pipeline HIV drug capravirine, after phase II studies highlighted limited efficacy and tolerability issues compared to other products. However, Pfizer has another, and perhaps more impressive, trick up its sleeve, namely its promising CCR5 inhibitor maraviroc.
14 Jul 05
The field of histone deacetylase inhibitors is moving into a new phase of development with candidates advancing nicely through clinical development. Milkana hasve recently developed a series of non-hydroxamic histone deactylase inhibitors which are likely to demonstrate an improved toxcity profile
13 Jul 05
Anxiety disorders affect 20% of the total population across the seven major markets. Recent data demonstrates the efficacy of MPEP, the prototypical mGlu5 receptor antagonist as a an anxiolytic. Efficacy was similar compared to that of diazepam but at anxiolytic doses produces less cognitive decline
08 Jul 05
Altana and Pfizer have terminated an agreement to develop the respiratory disease drug Daxas following unimpressive phase III results. Altana will continue Daxas' development, but additional trials may be required. Pfizer, meanwhile, will focus efforts on an alternative in-house compound, with an eye on developing a dual-action COPD product.
08 Jul 05
DailyUpdates was developed in 2002 by the drug development consultants, LeadDiscovery. Developed for the R&D community, 1,000's of individuals plus many of the top 20 pharmaceutical companies now use this simple yet effective tool to track key events in the drug discovery sector.
06 Jul 05
The field of histone deacetylase inhibitors is moving into a new phase of development. The exponential growth in the level of research activity surrounding the histone deacetylases (HDACs) witnessed over the past decade has now started to produce success in the clinic, particularly in the field of oncology. Over the next few years experts believe that as first generation HDAC inhibitors produce clinical benefits and second generation inhibitors are rationally designed with improved specificity
01 Jul 05
Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This report evaluates this exciting area of drug discovery
29 Jun 05
Welcome to the June edition of TherapeuticAdvances, LeadDiscovery's free newsletter for the drug development sector. Read on for editorial comment on selected studies recently featured on DailyUpdates our regular bulletin of breaking journal articles and drug development news
28 Jun 05
Despite recent advances in the treatment and management of hepatitis B, the market is still relatively immature, with several key unmet needs. Current pipeline products are expected to account for 89% of total market sales by 2015, however other developmental antivirals are also expected to contribute significantly to future market growth, potentially resulting in new treatment paradigms.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.